ASLAN PHARMACEUTICALS
ASLAN is a pharmaceutical company that develops novel medicines for global markets. It specializes in clinical-stage immunology and oncology-focused biopharmaceuticals.
ASLAN PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Oncology Pharmaceutical
Founded:
2010-01-01
Address:
Singapore, Central Region, Singapore
Country:
Singapore
Website Url:
http://www.aslanpharma.com
Total Employee:
11+
Status:
Active
Contact:
65-6222-4235
Email Addresses:
[email protected]
Total Funding:
186 M USD
Technology used in webpage:
Google Maps IPv6 Contact Form 7 Google Maps API Microsoft CPanel Smart App Banner Google No Translate Akamai Hosted Schema Plugin
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
CStone Pharmaceuticals
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Current Employees Featured
Founder
Stock Details
Investors List
K2 HealthVentures
K2 HealthVentures investment in Post-IPO Debt - ASLAN Pharmaceuticals
Armentum Partners
Armentum Partners investment in Post-IPO Debt - ASLAN Pharmaceuticals
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - ASLAN Pharmaceuticals
Vivo Capital
Vivo Capital investment in Post-IPO Equity - ASLAN Pharmaceuticals
Milestone Capital China
Milestone Capital China investment in Series D - ASLAN Pharmaceuticals
KGI Venture Capital
KGI Venture Capital investment in Series D - ASLAN Pharmaceuticals
TopTaiwan
TopTaiwan investment in Series D - ASLAN Pharmaceuticals
Taya Ventures
Taya Ventures investment in Series D - ASLAN Pharmaceuticals
Taiwan institutional funds
Taiwan institutional funds investment in Series D - ASLAN Pharmaceuticals
Daiwa Corporate Investment
Daiwa Corporate Investment investment in Series D - ASLAN Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-15 | ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer |
Official Site Inspections
http://www.aslanpharma.com Semrush global rank: 1.59 M Semrush visits lastest month: 14.87 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ASLAN Pharmaceuticals"
ASLAN Pharmaceuticals - Crunchbase Company Profile …
Organization. ASLAN Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email [email protected]; Phone Number 65-6222-4235; …See details»
Corporate Governance - ASLAN Pharmaceuticals
ASLAN Pharmaceuticals is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients.See details»
Organization | Aslan Pharmaceuticals
Organization Overview. First Clinical Trial. 2012 NCT01614522. First Marketed Drug. None First NDA Approval. None ... ASLAN Pharmaceuticals Pte Ltd | [email protected] Active …See details»
SEC Filing - ASLAN Pharmaceuticals
Feb 9, 2021 incorporation or organization) (I.R.S. Employer. Identification Number) 83 Clemenceau Avenue #12-03 UE Square . Singapore 239920 ... New York, New York 10016. …See details»
ASLAN Pharmaceuticals - Overview, News & Similar companies
May 21, 2024 ASLAN Pharmaceuticals contact info: Phone number: +65 62224235 Website: www.aslanpharma.com What does ASLAN Pharmaceuticals do? ASLAN Pharmaceuticals is a …See details»
ASLAN Pharmaceuticals Company Profile | Management and
Www.aslanpharma.com ASLAN Pharmaceuticals Profile and History ASLAN Pharmaceuticals is a clinical-stage immunology focused biopharmaceutical company developing innovative …See details»
ASLAN Pharmaceuticals - LinkedIn
ASLAN Pharmaceuticals | 4,991 followers on LinkedIn. A clinical-stage immunology focused biopharmaceutical company. | ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage …See details»
Company Description - Stock Analysis
Ticker Symbol: ASLN: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: CIK Code: 0001722926: CUSIP Number: 04522R101: ISIN Number: …See details»
ASLAN Pharmaceuticals - Craft
Sep 4, 2024 ASLAN Pharmaceuticals has 5 employees across 4 locations and $12 m in annual revenue in FY 2023. See insights on ASLAN Pharmaceuticals including office locations, …See details»
ASLAN Pharmaceuticals Limited (ASLN) - Stock Analysis
Jul 18, 2024 Website https://aslanpharma.com. Full Company Profile. Financial Performance. Financial Statements. Analyst Forecast. According to 3 analysts, the average rating for ASLN …See details»
ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic …
MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical …See details»
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 ...
Mar 25, 2022 Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) underway with topline data expected in the first half of 2023New CMO appointed, adding …See details»
Press Releases - ASLAN Pharmaceuticals
May 2, 2024 The Investor Relations website contains information about ASLAN Pharmaceuticals's business for stockholders, potential investors, and financial analysts.See details»
Recommended Stories
Feb 24, 2023 The financing, which is subject to customary closing conditions, is expected to close on or about February 27, 2023. Pursuant to the terms of the Purchase Agreement, …See details»
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial …
May 9, 2024 Positive interim data readout from 22 patients in TREK-DX study of eblasakimab showed unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with …See details»
ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial …
Sep 30, 2023 In October, ASLAN co-hosted a panel discussion with a leading Clinical Research Organization entitled, “The Changing Face of Atopic Dermatitis: How the Clinical Trial and …See details»
ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic
Dec 6, 2021 MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Pte Ltd (Nasdaq: ASLN), a clinical-stage, immunology-focused …See details»
ASLAN Pharmaceuticals and IQVIA Biotech Enter Into
Dec 6, 2021 Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: [email protected] Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430 …See details»
ASLAN Pharmaceuticals Reports First Quarter 2023 Financial …
Mar 31, 2023 Data readout for TREK-AD Phase 2b study of eblasakimab on track for early July 2023; Four abstracts on eblasakimab and farudodstat, including two late-breakers, to be …See details»